loading page

Mucosal Fixed Drug Eruption to Levetiracetam with Early Positive Patch Test on Non-Lesional Skin
  • Nazli Ercan
Nazli Ercan
University of Health Sciences Turkey

Corresponding Author:[email protected]

Author Profile


Levetiracetam (LEV) is a second-generation antiepileptic drug (AED) that is well tolerated, has a broad spectrum of action, low protein binding, and minimal hepatic metabolism. The incidence of hypersensitivity to LEV in children and adults is 0.6%. This is the first reported fixed drug eruption (FDE) identified using a patch test in a pediatric case associated with LEV
31 Oct 2021Submitted to Pediatric Allergy and Immunology
03 Nov 2021Reviewer(s) Assigned
13 Nov 2021Review(s) Completed, Editorial Evaluation Pending
15 Nov 2021Editorial Decision: Revise Major
09 Dec 20211st Revision Received
10 Dec 2021Review(s) Completed, Editorial Evaluation Pending
10 Dec 2021Reviewer(s) Assigned
17 Dec 2021Editorial Decision: Accept
Feb 2022Published in Pediatric Allergy and Immunology volume 33 issue 2. 10.1111/pai.13723